Priti Kumar, PhD
Research & Publications
Biography
News
Extensive Research Description
Dr. Kumar's training in virology and immunology and her dissertation identified the non-structural protein 3 of the Japanese encephalitis virus (JEV) as an important vaccine candidate through the protective immune response this protein elicited in asymptomatically-infected individuals, which also reduced neurological symptoms in symptomatically-ill cohorts in the JEV-endemic regions in South India. Her thesis work was published as 6 first-authored papers in international, well-recognized peer-reviewed journals. For her post-doctoral studies, she pioneered the use of siRNAs for treating flaviviral infections and developed a platform for the transvascular delivery of siRNA into the CNS using a peptide from the Rabies virus (PLOS Medicine, 2006; Nature, 2007). Continuance of this research interested at Yale has continued to be the advancement of novel therapeutic strategies for acute infections caused by Zika and West Nile virus. Work from the laboratory has demonstrated that intranasal administration of siRNAs with RVG at late stages of West Nile virus encephalitis can prevent a fatal outcome while promoting long-term immunity (Cell Host and Microbe, 2018).
Kumar P, Sulochana P, Nirmala G, Chandrashekar R, Haridattatreya M, Satchidanandam V. Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae. J Infect Dis. 2004 189(5):880-91.
Kumar P, Lee SK, Shankar P and Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLOS Medicine 2006 3(4):e96.
Kumar P, Wu H, McBride JL, Jung KE, Moon Hee Kim, Davidson BL, Lee SK, Shankar P and Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007. 448(7149):39-43.
Beloor J, Maes N, Ullah I, Uchil P, Jackson A, Fikrig E, Lee, SK and Kumar P*. Small interfering RNA-mediated control of virus replication in the CNS is therapeutic and enables natural immunity to West Nile virus. Cell Host and Microbe 2018. 23(4):549-556. PMC6074029.
See Also: Comment Barouch-Bentov R, Einav S. Turning Up Your Nose for a Flaviviral Encephalitis Cure. Cell Host Microbe. 2018; 23(4):427-429. PMID: 29649437; PMC7104965.
A major strength of the Kumar laboratory is expertise in humanized mouse models for HIV infection. This has resulted in many successful collaborations and co-authored manuscriptsas well as consultations for opinion and work shops at the NIH in advancing humanized mouse models for the study of HIV-1. In collaboration with the Mothes laboratory at Yale, the Kumar lab identified a critical role for macrophages expressing CD169 in the in vivo capture of retroviruses at lymphoid organs for transinfecting virus-susceptible target cells. The mechanism appears to be a common route for transmission of both murine (MLV) and human (HIV) retroviruses in animal models of infection (Science, 2015). Along the lines of treatment with the Anderson and Saltzman laboratories at Yale, the Kumar lab has been investigating the potency of novel picomolar NNRTIs as a treatment for HIV-AIDS as long-acting formulations (Mol. Pharmacology, 2017; PNAS USA, 2018, ).
Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, and Zack JA. Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. AIDS Res Hum Retroviruses. 2016; 32(2):109-19. PMCID: PMC4761823.
Sewald X, Ladinsky MS, Uchil1 PD, Beloor J, Pi R, Herrmann1C, Motamedi N, Murooka TT, Brehm MA, Greiner DL, Shultz LD, Mempel TR, Bjorkman PJ, Kumar P*, and Mothes W. Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science. 2015, Oct 30;350(6260):563-7. PMC4651917
Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P*, Jorgensen WL, Anderson KS. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci U S A. 2018 ;115(4):E802-E811. PMC5789948
Ventura JD, Beloor J, Allen E, Zhang T, Haugh KA, Uchil PD, Ochsenbauer C, Kieffer C, Kumar P*, Hope TJ, Mothes W. Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLoS Pathog. 2019; 15(12):e1008161. PMCID: PMC6917343.
An important focus of my research is in vivo gene-therapy. My laboratory develops gene delivery platforms to enable gene and oligonucleotide delivery in a highly targeted manner to specific cell types in vivo. This is of immense significance as it obviates the need for ex-vivo manipulation of cells and transplantation protocols. The advantage of these systems is that they enable delivery to cells like neurons, human T cells and hematopoietic stem cells that are extremely resilient to nucleic acid uptake. We have contributed to the field of gene delivery by studying mechanisms for direct delivery of nucleic acids into the cytoplasm (eg: Chemistry and Biology, 2015); developing delivery systems for efficient nucleic acid delivery to hard-to-transfect cells like embryonic stem cells, neurons and T cells (eg: Small, 2015; Cell, 2008) and adapting these delivery systems for the treatment of viral and metabolic diseases in preclinical animal models (Nature 2007; Molecular Therapy Nucleic Acids, 2016).
Zeller S, Choi CS, Uchil PD, Ban HS, Siefert A, Fahmy TM, Mothes W, Lee SK, Kumar P*. Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA. Chemistry & Biology. 2015; 22(1):50-62. PMC4320807
Beloor J, Ramakrishna S, Nam K, Seon Choi C, Kim J, Kim SH, Cho HJ, Shin H, Kim H, Kim SW, Lee SK, Kumar P*. Effective gene delivery into human stem cells with a cell-targeting Peptide-modified bioreducible polymer. 2015; 11(17):2069-79.
Kim J, Chung K, Choi C, Beloor J, Ullah I, Kim N, Lee KY, Lee SK, Kumar P*. Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. Molecular Therapy Nucleic acids. 2016; 5:e280. PMC5012549
Ullah I, Chung K, Beloor J, Kim J, Cho M, Kim N, Lee KY, Kumar P*, Lee SK. Trileucine residues in a ligand-CPP-based siRNA delivery platform improve endosomal escape of siRNA. J Drug Target. 2017; 25(4):320-329. PMID: 27820977.
Coauthors
Research Interests
T-Lymphocytes; RNA Interference; Infectious Disease Medicine; Molecular Targeted Therapy
Selected Publications
- The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in miceUllah I, Beaudoin-Bussières G, Symmes K, Cloutier M, Ducas E, Tauzin A, Laumaea A, Grunst M, Dionne K, Richard J, Bégin P, Mothes W, Kumar P, Bazin R, Finzi A, Uchil P. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine 2022, 4: 100893. PMID: 36584683, PMCID: PMC9799175, DOI: 10.1016/j.xcrm.2022.100893.
- Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBDChen Y, Prévost J, Ullah I, Romero H, Lisi V, Tolbert W, Grover J, Ding S, Gong S, Beaudoin-Bussières G, Gasser R, Benlarbi M, Vézina D, Anand S, Chatterjee D, Goyette G, Grunst M, Yang Z, Bo Y, Zhou F, Béland K, Bai X, Zeher A, Huang R, Nguyen D, Sherburn R, Wu D, Piszczek G, Paré B, Matthies D, Xia D, Richard J, Kumar P, Mothes W, Côté M, Uchil P, Lavallée V, Smith M, Pazgier M, Haddad E, Finzi A. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. IScience 2022, 26: 105783. PMID: 36514310, PMCID: PMC9733284, DOI: 10.1016/j.isci.2022.105783.
- OP 6.2 – 00195 Targeted genome engineering of human t cells in vivo for HIV cureKumar P, Beloor J, Krishnaswamy J, Ullah I, Uchil P. OP 6.2 – 00195 Targeted genome engineering of human t cells in vivo for HIV cure. Journal Of Virus Eradication 2022, 8: 100247. DOI: 10.1016/j.jve.2022.100247.
- HIV-1 Vpu restricts Fc-mediated effector functions in vivoPrévost J, Anand S, Rajashekar J, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen H, Chen Y, Horwitz J, Grunst M, Zolla-Pazner S, Haynes B, Burton D, Flavell R, Kirchhoff F, Hahn B, Smith A, Pazgier M, Nussenzweig M, Kumar P, Finzi A. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Reports 2022, 41: 111624. PMID: 36351384, PMCID: PMC9703018, DOI: 10.1016/j.celrep.2022.111624.
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesChen Y, Sun L, Ullah I, Beaudoin-Bussières G, Anand SP, Hederman AP, Tolbert WD, Sherburn R, Nguyen DN, Marchitto L, Ding S, Wu D, Luo Y, Gottumukkala S, Moran S, Kumar P, Piszczek G, Mothes W, Ackerman ME, Finzi A, Uchil PD, Gonzalez FJ, Pazgier M. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Science Advances 2022, 8: eabn4188. PMID: 35857504, PMCID: PMC9278865, DOI: 10.1126/sciadv.abn4188.
- VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entryDing S, Ullah I, Gong SY, Grover J, Mohammadi M, Chen Y, Vézina D, Beaudoin-Bussières G, Verma VT, Goyette G, Gaudette F, Richard J, Yang D, Smith AB, Pazgier M, Côté M, Abrams C, Kumar P, Mothes W, Uchil P, Finzi A, Baron C. VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry. IScience 2022, 25: 104528. PMID: 35677392, PMCID: PMC9164512, DOI: 10.1016/j.isci.2022.104528.
- A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infectionBeaudoin-Bussières G, Chen Y, Ullah I, Prévost J, Tolbert WD, Symmes K, Ding S, Benlarbi M, Gong SY, Tauzin A, Gasser R, Chatterjee D, Vézina D, Goyette G, Richard J, Zhou F, Stamatatos L, McGuire AT, Charest H, Roger M, Pozharski E, Kumar P, Mothes W, Uchil PD, Pazgier M, Finzi A. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Reports 2022, 38: 110368. PMID: 35123652, PMCID: PMC8786652, DOI: 10.1016/j.celrep.2022.110368.
- Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concernLi W, Chen Y, Prévost J, Ullah I, Lu M, Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP, Goyette G, Chaterjee D, Ding S, Tolbert WD, Grunst MW, Bo Y, Zhang S, Richard J, Zhou F, Huang RK, Esser L, Zeher A, Côté M, Kumar P, Sodroski J, Xia D, Uchil PD, Pazgier M, Finzi A, Mothes W. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Reports 2021, 38: 110210. PMID: 34971573, PMCID: PMC8673750, DOI: 10.1016/j.celrep.2021.110210.
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.Chen Y, Sun L, Ullah I, Beaudoin-Bussières G, Anand SP, Hederman AP, Tolbert WD, Sherburn R, Nguyen DN, Marchitto L, Ding S, Wu D, Luo Y, Gottumukkala S, Moran S, Kumar P, Piszczek G, Mothes W, Ackerman ME, Finzi A, Uchil PD, Gonzalez FJ, Pazgier M. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. BioRxiv : The Preprint Server For Biology 2021 PMID: 34845451, PMCID: PMC8629194, DOI: 10.1101/2021.11.24.469776.
- Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacyUllah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Symmes K, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, Bourassa C, Medjahed H, Mack M, Chung K, Wilen CB, Dekaban GA, Dikeakos JD, Bruce EA, Kaufmann DE, Stamatatos L, McGuire AT, Richard J, Pazgier M, Bjorkman PJ, Mothes W, Finzi A, Kumar P, Uchil PD. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity 2021, 54: 2143-2158.e15. PMID: 34453881, PMCID: PMC8372518, DOI: 10.1016/j.immuni.2021.08.015.
- Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy.Ullah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Symmes K, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, Bourassa C, Medjahed H, Mack M, Chung K, Wilen CB, Dekaban GA, Dikeakos JD, Bruce EA, Kaufmann DE, Stamatatos L, McGuire AT, Richard J, Pazgier M, Bjorkman PJ, Mothes W, Finzi A, Kumar P, Uchil PD. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. BioRxiv : The Preprint Server For Biology 2021 PMID: 33791699, PMCID: PMC8010726, DOI: 10.1101/2021.03.22.436337.
- Long‐acting and extended‐release implant and nanoformulations with a synergistic antiretroviral two‐drug combination controls HIV‐1 infection in a humanized mouse modelBeloor J, Kudalkar SN, Buzzelli G, Yang F, Mandl HK, Rajashekar JK, Spasov KA, Jorgensen WL, Saltzman WM, Anderson KS, Kumar P. Long‐acting and extended‐release implant and nanoformulations with a synergistic antiretroviral two‐drug combination controls HIV‐1 infection in a humanized mouse model. Bioengineering & Translational Medicine 2021, 7: e10237. PMID: 35079625, PMCID: PMC8780078, DOI: 10.1002/btm2.10237.
- Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoirRajashekar JK, Richard J, Beloor J, Prévost J, Anand SP, Beaudoin-Bussières G, Shan L, Herndler-Brandstetter D, Gendron-Lepage G, Medjahed H, Bourassa C, Gaudette F, Ullah I, Symmes K, Peric A, Lindemuth E, Bibollet-Ruche F, Park J, Chen HC, Kaufmann DE, Hahn BH, Sodroski J, Pazgier M, Flavell RA, Smith AB, Finzi A, Kumar P. Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host & Microbe 2021, 29: 904-916.e6. PMID: 34019804, PMCID: PMC8214472, DOI: 10.1016/j.chom.2021.04.014.
- Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral InfectionsMaes N, Zeller S, Kumar P. Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections. 2021, 223-264. DOI: 10.1201/9781003125259-8.
- Targeted Delivery of Recombinant Heat Shock Protein 27 to Cardiomyocytes Promotes Recovery from Myocardial InfarctionKim N, Ullah I, Chung K, Lee D, Cha MJ, Ban H, Choi CS, Kim S, Hwang KC, Kumar P, Lee SK. Targeted Delivery of Recombinant Heat Shock Protein 27 to Cardiomyocytes Promotes Recovery from Myocardial Infarction. Molecular Pharmaceutics 2020, 17: 2034-2043. PMID: 32364395, DOI: 10.1021/acs.molpharmaceut.0c00192.
- Single cell immune profiling of dengue virus patients reveals intact immune responses to Zika virus with enrichment of innate immune signaturesZhao Y, Amodio M, Wyk B, Gerritsen B, Kumar MM, van Dijk D, Moon K, Wang X, Malawista A, Richards MM, Cahill ME, Desai A, Sivadasan J, Venkataswamy MM, Ravi V, Fikrig E, Kumar P, Kleinstein SH, Krishnaswamy S, Montgomery RR. Single cell immune profiling of dengue virus patients reveals intact immune responses to Zika virus with enrichment of innate immune signatures. PLOS Neglected Tropical Diseases 2020, 14: e0008112. PMID: 32150565, PMCID: PMC7082063, DOI: 10.1371/journal.pntd.0008112.
- Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized miceVentura JD, Beloor J, Allen E, Zhang T, Haugh KA, Uchil PD, Ochsenbauer C, Kieffer C, Kumar P, Hope TJ, Mothes W. Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLOS Pathogens 2019, 15: e1008161. PMID: 31805155, PMCID: PMC6917343, DOI: 10.1371/journal.ppat.1008161.
- A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System.Ullah I, Chung K, Beloor J, Lee SK, Kumar P. A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System. Journal Of Visualized Experiments 2019 PMID: 31475960, DOI: 10.3791/59201.
- A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous SystemUllah I, Chung K, Beloor J, Lee S, Kumar P. A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System. Journal Of Visualized Experiments 2019 DOI: 10.3791/59201-v.
- Introducing Genes into Cultured Mammalian CellsKumar P, Nagarajan A, Uchil PD. Introducing Genes into Cultured Mammalian Cells. Cold Spring Harbor Protocols 2019, 2019: pdb.top095406. PMID: 31285274, DOI: 10.1101/pdb.top095406.
- DNA Transfection by Electroporation.Kumar P, Nagarajan A, Uchil PD. DNA Transfection by Electroporation. Cold Spring Harbor Protocols 2019, 2019: pdb.prot095471. PMID: 31262956, DOI: 10.1101/pdb.prot095471.
- ElectroporationKumar P, Nagarajan A, Uchil PD. Electroporation. Cold Spring Harbor Protocols 2019, 2019: pdb.top096271. PMID: 31262965, DOI: 10.1101/pdb.top096271.
- DNA Transfection Mediated by Cationic Lipid ReagentsKumar P, Nagarajan A, Uchil PD. DNA Transfection Mediated by Cationic Lipid Reagents. Cold Spring Harbor Protocols 2019, 2019: pdb.prot095414. PMID: 30824617, DOI: 10.1101/pdb.prot095414.
- Histochemical Staining of Cell Monolayers for β-Galactosidase.Kumar P, Nagarajan A, Uchil PD. Histochemical Staining of Cell Monolayers for β-Galactosidase. Cold Spring Harbor Protocols 2019, 2019: pdb.prot095422. PMID: 30824618, DOI: 10.1101/pdb.prot095422.
- Lipofection.Kumar P, Nagarajan A, Uchil PD. Lipofection. Cold Spring Harbor Protocols 2019, 2019: pdb.top096248. PMID: 30824627, DOI: 10.1101/pdb.top096248.
- Small Interfering RNA-Mediated Control of Virus Replication in the CNS Is Therapeutic and Enables Natural Immunity to West Nile VirusBeloor J, Maes N, Ullah I, Uchil P, Jackson A, Fikrig E, Lee SK, Kumar P. Small Interfering RNA-Mediated Control of Virus Replication in the CNS Is Therapeutic and Enables Natural Immunity to West Nile Virus. Cell Host & Microbe 2018, 23: 549-556.e3. PMID: 29606496, PMCID: PMC6074029, DOI: 10.1016/j.chom.2018.03.001.
- From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infectionKudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 115: e802-e811. PMID: 29279368, PMCID: PMC5789948, DOI: 10.1073/pnas.1717932115.
- Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID “Meet the Experts” 2015 Workshop SummaryAkkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, Zack JA. Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID “Meet the Experts” 2015 Workshop Summary. AIDS Research And Human Retroviruses 2016, 32: 109-119. PMID: 26670361, PMCID: PMC4761823, DOI: 10.1089/aid.2015.0258.
- Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese MiceKim J, Chung K, Choi C, Beloor J, Ullah I, Kim N, Lee KY, Lee SK, Kumar P. Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. Molecular Therapy - Nucleic Acids 2016, 5: e280. PMID: 26812653, PMCID: PMC5012549, DOI: 10.1038/mtna.2015.51.
- Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infectionSewald X, Ladinsky MS, Uchil PD, Beloor J, Pi R, Herrmann C, Motamedi N, Murooka TT, Brehm MA, Greiner DL, Shultz LD, Mempel TR, Bjorkman PJ, Kumar P, Mothes W. Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science 2015, 350: 563-567. PMID: 26429886, PMCID: PMC4651917, DOI: 10.1126/science.aab2749.
- Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized MiceLiu S, Jackson A, Beloor J, Kumar P, Sutton RE. Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice. Human Gene Therapy 2015, 26: 622-634. PMID: 25953321, PMCID: PMC4575530, DOI: 10.1089/hum.2014.146.
- Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutationsDeng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 2015, 517: 381-385. PMID: 25561180, PMCID: PMC4406054, DOI: 10.1038/nature14053.
- Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides Enables Cytosolic Translocation of Complexed siRNAZeller S, Choi CS, Uchil PD, Ban HS, Siefert A, Fahmy TM, Mothes W, Lee SK, Kumar P. Attachment of Cell-Binding Ligands to Arginine-Rich Cell-Penetrating Peptides Enables Cytosolic Translocation of Complexed siRNA. Cell Chemical Biology 2014, 22: 50-62. PMID: 25544044, PMCID: PMC4320807, DOI: 10.1016/j.chembiol.2014.11.009.
- Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized MiceSchleifman EB, McNeer NA, Jackson A, Yamtich J, Brehm MA, Shultz LD, Greiner DL, Kumar P, Saltzman WM, Glazer PM. Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. Molecular Therapy - Nucleic Acids 2013, 2: e135. PMID: 24253260, PMCID: PMC3889188, DOI: 10.1038/mtna.2013.59.
- Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral InfectionsMaes N, Zeller S, Kumar P. Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections. 2012, 199-239. DOI: 10.1201/b11620-8.
- T.86. siRNA Delivery with Integrin LFA-1-targeted Nanoparticles Prevents HIV Infection in Humanized MiceKim S, Peer D, Kumar P, Shimaoka M, Shankar P. T.86. siRNA Delivery with Integrin LFA-1-targeted Nanoparticles Prevents HIV Infection in Humanized Mice. Clinical Immunology 2009, 131: s75-s76. DOI: 10.1016/j.clim.2009.03.221.
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceKumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice. Cell 2008, 134: 577-586. PMID: 18691745, PMCID: PMC2943428, DOI: 10.1016/j.cell.2008.06.034.
- Transvascular delivery of small interfering RNA to the central nervous systemKumar P, Wu H, McBride JL, Jung KE, Hee Kim M, Davidson BL, Kyung Lee S, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448: 39-43. PMID: 17572664, DOI: 10.1038/nature05901.
- Screening for T cell-eliciting proteins of Japanese encephalitis virus in a healthy JE-endemic human cohort using recombinant baculovirus-infected insect cell preparationsKumar P, Uchil PD, Sulochana P, Nirmala G, Chandrashekar R, Haridattatreya M, Satchidanandam V. Screening for T cell-eliciting proteins of Japanese encephalitis virus in a healthy JE-endemic human cohort using recombinant baculovirus-infected insect cell preparations. Archives Of Virology 2003, 148: 1569-1591. PMID: 12898332, DOI: 10.1007/s00705-003-0118-5.
- Ethyleneglycol-Bis-(β-Aminoethylether)Tetraacetate as a Blood Anticoagulant: Preservation of Antigen-Presenting Cell Function and Antigen-Specific Proliferative Response of Peripheral Blood Mononuclear Cells from Stored BloodKumar P, Satchidanandam V. Ethyleneglycol-Bis-(β-Aminoethylether)Tetraacetate as a Blood Anticoagulant: Preservation of Antigen-Presenting Cell Function and Antigen-Specific Proliferative Response of Peripheral Blood Mononuclear Cells from Stored Blood. MSphere 2000, 7: 578-583. PMID: 10882655, PMCID: PMC95917, DOI: 10.1128/cdli.7.4.578-583.2000.